Skip to main content
PZ Cormay S.A. logo

PZ Cormay S.A. — Investor Relations & Filings

Ticker · CRM ISIN · PLCMRAY00029 LEI · 2594006HZJ8OSNK56U87 WAR Manufacturing
Open in API
Filings indexed 692 across all filing types
Latest filing 2016-12-13 Capital/Financing Update
Country PL Poland
Listing WAR CRM

About PZ Cormay S.A.

https://cormaydiagnostics.com/

PZ Cormay S.A. is a manufacturer and distributor of in-vitro diagnostic (IVD) solutions for medical laboratories and clinics. The company develops, produces, and sells a comprehensive portfolio of diagnostic reagents, laboratory analyzers, and quality control systems. Its offerings cater to key diagnostic areas, including clinical chemistry, hematology, and immunoassay. Key product lines feature the Accent series of chemistry analyzers, the Auryx immunoassay system, and the Mythic family of hematology analyzers. The company integrates its extensive experience in reagent manufacturing with advanced Swiss hematology technology to provide reliable, high-performance, and cost-effective diagnostic tools to a global network of distributors and healthcare professionals.

Recent filings

Filing Released Lang Actions
Złożenie Prospektu Emisyjnego w KNF - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text, written in Polish, discusses the filing of an application ('wniosek') with the Polish Financial Supervision Authority ('Urzędu Komisji Nadzoru Finansowego') for the approval of an issuance prospectus ('prospektu emisyjnego') related to a public offering of new shares ('Akcje Oferowane'). This action is directly related to capital structure changes, fundraising, and the subsequent listing of shares on the Warsaw Stock Exchange. This clearly falls under the definition of Capital/Financing Update (CAP), as it details the process of issuing new shares via a public offer.
2016-12-13 Polish
Decyzja o przeglądzie opcji strategicznych związanych z posiadaniem przez spółkę zależną Emitenta - Orphée S.A., znacznego pakietu akcji spółki Diesse Diagnostica Senese S.p.A. - Content (PL)
M&A Activity Classification · 95% confidence The document is a formal announcement from the Management Board (Zarząd) of PZ Cormay S.A. regarding a strategic review of options concerning a significant stake in a subsidiary's holding (Orphée S.A.'s stake in Diesse Diagnostica). The content discusses potential strategic actions like finding an external investor or acquiring remaining shares. This type of announcement, detailing strategic considerations and potential future corporate actions involving capital structure or significant assets, aligns best with the 'Capital/Financing Update' category, as it directly relates to the structure and financing of the group's assets. Although it discusses strategy, the core action being considered is a transaction affecting capital holdings. It is not a standard earnings release (ER), interim report (IR), or a formal M&A bid (TAR), but rather an initial disclosure of strategic options related to asset disposition/acquisition. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate fit for disclosing a strategic review of significant asset holdings/financing options.
2016-12-09 Polish
Wyrok Sądu I instancji oddalający w całości powództwo byłego członka Zarządu Emitenta o stwierdzenie nieistnienia, alternatywnie stwierdzenie nieważności, alternatywnie uchylenie uchwał Nadzwyczajn...
Legal Proceedings Report Classification · 98% confidence The document text is written in Polish and discusses the outcome of a lawsuit filed by a former board member against the company (PZ Cormay S.A.) concerning the validity of resolutions passed during an Extraordinary General Meeting (NWZA) regarding the Supervisory Board. The text explicitly details the court's decision to dismiss the lawsuit, confirming the validity of the prior shareholder resolutions. This content directly relates to significant legal matters and regulatory actions involving the company. Therefore, it fits the definition of a Legal Proceedings Report (LTR). The document is a substantive update on a legal case, not merely an announcement of a report's publication.
2016-11-21 Polish
Raport 3Q 2016
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'SKONSOLIDOWANY RAPORT KWARTALNY' (Consolidated Quarterly Report) for Grupa Kapitałowa PZ CORMAY, covering the 9-month period ending September 30, 2016. It contains detailed financial statements (consolidated and individual), notes to the financial statements, and management information. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2016
2016-11-14 Polish
List Prezeza
Interim / Quarterly Report Classification · 90% confidence The document is a letter from the CEO of PZ Cormay S.A. introducing the consolidated quarterly report for Q3 2016. While it summarizes key financial figures (revenue, EBITDA, net loss) and discusses strategic projects, it functions as a management commentary/letter accompanying the report rather than the full financial statements themselves. However, given the substantive financial data provided and the context of it being a quarterly update, it aligns best with the 'Interim / Quarterly Report' category as it provides a comprehensive overview of the period's performance. 9M 2016
2016-11-14 Polish
Informacja o wyborze projektu do dofinansowania przez Polską Agencję Rozwoju Przedsiębiorczości - Content (PL)
Regulatory Filings Classification · 92% confidence The document is a formal announcement (indicated by 'Zarząd PZ CORMAY S.A. ... informuje') from a Polish company regarding the selection of its project for co-financing by the Polish Agency for Enterprise Development (Polska Agencja Rozwoju Przedsiębiorczości) under a specific program ('Go to Brand'). The content details the project's goals, which focus heavily on export expansion, participation in trade fairs, and market entry into Asian and Arab markets. This is not a standard financial report (10-K, IR, ER), nor is it a management change (MANG) or dividend notice (DIV). It specifically relates to receiving funding or support for business development/export promotion, which aligns best with Capital/Financing Update (CAP) as it concerns securing significant external funding/grants for expansion, or potentially Regulatory Filings (RNS) if viewed as a general regulatory disclosure. Given the focus on securing a specific grant/financing for expansion, CAP is a strong fit, but since it is a disclosure about receiving a grant/support for a specific business activity rather than raising capital through debt/equity, and it is a specific regulatory disclosure about an external decision affecting the company, RNS (Regulatory Filings) serves as a robust fallback for non-standard disclosures. However, since the core subject is the successful application for and receipt of a significant financial grant/support for expansion, classifying it as a Capital/Financing Update (CAP) related to non-equity financing is appropriate. Given the nature of the disclosure (announcing selection for a government grant), RNS is often used for such specific regulatory announcements not covered elsewhere. I will lean towards RNS as it is a disclosure about an external regulatory/agency decision impacting the company's operations/finances, which is a common use case for RNS when CAP is reserved for debt/equity issuance.
2016-10-24 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.